Drug Development for Intraperitoneal Chemotherapy Against Peritoneal Carcinomatosis from Gastrointestinal Cancer

Overview

Journal Surg Today

Specialty General Surgery

Date 2014 Feb 1

PMID 24482110

Citations 8

Authors

Shigenobu Emoto

Eiji Sunami

Hironori Yamaguchi

Soichiro Ishihara

Joji Kitayama

Toshiaki Watanabe

Affiliations

Soon will be listed here.

Abstract

Intraperitoneal (IP) chemotherapy for peritoneal carcinomatosis (PC) from gastrointestinal cancer has been investigated and applied clinically for several decades. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy have been considered to be the optimal treatment options for selected patients with colorectal and gastric cancers with PC. Accumulating evidence suggests that the administration of IP paclitaxel for patients with PC from gastric cancer may improve the patient survival. The pharmacokinetics of such treatment should be considered to optimize IP chemotherapy. In addition, newly emerging molecular-targeted therapies and research into new drug delivery systems, such as nanomedicine or controlled absorption/release methods, are essential to improve the effects of IP chemotherapy. This review summarizes the current status and future prospects of IP chemotherapy for the treatment of gastrointestinal cancer.

Citing Articles

Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease.

Li A, Sedighim S, Tajik F, Khan A, Radhakrishnan V, Dayyani F J Gastrointest Cancer. 2024; 55(2):534-548.

PMID: 38277055 PMC: 11186907. DOI: 10.1007/s12029-023-00994-5.

Bidirectional Chemotherapy in Advanced Colorectal Cancer Peritoneal Metastases.

Chatterjee A, Kazi M, Ostwal V, Ramaswamy A, DeSouza A, Saklani A Indian J Surg Oncol. 2023; 14(Suppl 1):192-197.

PMID: 37359918 PMC: 10284777. DOI: 10.1007/s13193-023-01715-x.

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial.

Senthil M, Dayyani F BMC Cancer. 2023; 23(1):209.

PMID: 36870941 PMC: 9985848. DOI: 10.1186/s12885-023-10680-1.

High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.

Coccolini F, Acocella F, Morosi L, Brizzola S, Ghiringhelli M, Ceresoli M Pharm Res. 2017; 34(6):1180-1186.

PMID: 28247168 DOI: 10.1007/s11095-017-2132-4.

Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.

Amini A, Masoumi-Moghaddam S, Ehteda A, Liauw W, Morris D Am J Cancer Res. 2016; 6(2):350-69.

PMID: 27186409 PMC: 4859666.

References

Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N . Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010; 2(2):85-97. PMC: 2998933. DOI: 10.4251/wjgo.v2.i2.85. View

He C, Kim S, Lee D . In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release. 2008; 127(3):189-207. DOI: 10.1016/j.jconrel.2008.01.005. View

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009; 28(1):63-8. DOI: 10.1200/JCO.2009.23.9285. View

Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H . Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol. 2004; 25(4):841-8. View

Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H, Kitayama J . Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci. 2012; 103(7):1304-10. PMC: 7659395. DOI: 10.1111/j.1349-7006.2012.02274.x. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Pazdur R, Lassere Y, Soh L, Ajani J, Bready B, Soo E . Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994; 5(5):468-70. DOI: 10.1093/oxfordjournals.annonc.a058883. View

Echarri Gonzalez M, Green R, Muggia F . Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?. Oncology (Williston Park). 2011; 25(2):156-65, 170. View

Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C . A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010; 251(5):896-901. DOI: 10.1097/SLA.0b013e3181d9765d. View

10.

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View

11.

Urano M, Kuroda M, Nishimura Y . For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999; 15(2):79-107. DOI: 10.1080/026567399285765. View

12.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

13.

Matsumura Y, Kataoka K . Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009; 100(4):572-9. PMC: 11158079. DOI: 10.1111/j.1349-7006.2009.01103.x. View

14.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

15.

Yamada J, Kitayama J, Tsuno N, Yamashita H, Miyato H, Soma D . Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer. Cancer Lett. 2008; 272(2):307-15. DOI: 10.1016/j.canlet.2008.07.024. View

16.

Hribaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H . Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy. 2007; 53(6):410-7. DOI: 10.1159/000110005. View

17.

Ceelen W, Flessner M . Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2009; 7(2):108-15. DOI: 10.1038/nrclinonc.2009.217. View

18.

Einzig A, Neuberg D, Wiernik P, Grochow L, Ramirez G, ODwyer P . Phase II Trial of Paclitaxel in Patients with Advanced Colon Cancer Previously Untreated with Cytotoxic Chemotherapy: An Eastern Cooperative Oncology Group Trial (PA286). Am J Ther. 1996; 3(11):750-754. DOI: 10.1097/00045391-199611000-00003. View

19.

Shah D, Veith J, Bernacki R, Balthasar J . Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol. 2011; 68(4):951-8. DOI: 10.1007/s00280-011-1566-3. View

20.

Markman M . Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003; 4(5):277-83. DOI: 10.1016/s1470-2045(03)01074-x. View